Moxifloxacin-Induced QT Prolongation and Torsades: An Uncommon Effect of a Common Drug

被引：22

作者：

Badshah, Aaref ^{[1
]}

Janjua, Mohammad ^{[1
]}

Younas, Fahad ^{[1
]}

Halabi, Abdul R. ^{[2
]}

Cotant, John F. ^{[2
]}

机构：

[1] St Joseph Mercy Oakland, Dept Internal Med, Pontiac, MI 48341 USA

[2] St Joseph Mercy Oakland, Dept Cardiol, Pontiac, MI 48341 USA

来源：

AMERICAN JOURNAL OF THE MEDICAL SCIENCES | 2009年 / 338卷 / 02期

关键词：

Moxifloxacin; Prolonged QT interval; ECG; Torsade de pointes; LIFE-THREATENING ARRHYTHMIAS; DE-POINTES; FLUOROQUINOLONES; INTERVAL;

D O I：

10.1097/MAJ.0b013e3181a3c2c9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Torsade de pointes (TdP) or "twisting of the points" represents polymorphic ventricular tachycardia in the setting of prolonged QT interval and is characterized by QRS complexes that change in morphology and amplitude. We report a rare case of TdP, associated with QT interval prolongation, caused by intravenous moxifloxacin given for pneumonia in a 71-year-old African American man. Electrocardiogram initially revealed QT interval prolongation that led to torsades de pointes. These changes reverted to normal when moxifloxacin was held. Although the risk for quinolone-associated TdP seems to be low, caution is still warranted when given someone with high risk of QT prolongation.

引用

页码：164 / 166

页数：3

共 14 条

[1] Torsade de pointes associated with moxifloxacin: A rare but potentially fatal adverse event [J].

Altin, Timucin ;

Ozcan, Ozgur ;

Turhan, Sibel ;

Ozdemir, Aydan Ongun ;

Akyurek, Omer ;

Karaoguz, Remzi ;

Guldal, Muharrem .

CANADIAN JOURNAL OF CARDIOLOGY, 2007, 23 (11) :907-908

[2] The safety profile of the fluoroquinolones [J].

Bertino, J ;

Fish, D .

CLINICAL THERAPEUTICS, 2000, 22 (07) :798-817

[3] Moxifloxacin and torsaide de Pointes [J].

Dale, Krista M. ;

Lertsburapa, Kirkeith ;

Kluger, Jeffrey ;

White, C. Michael .

ANNALS OF PHARMACOTHERAPY, 2007, 41 (02) :336-340

[4] QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience [J].

De Ponti, F ;

Poluzzi, E ;

Montanaro, N .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (01) :1-18

[5] Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects [J].

Démolis, JL ;

Kubitza, D ;

Tennezé, L ;

Funck-Brentano, C .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (06) :658-666

[6] Rates of Torsades de Pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin [J].

Frothingham, R .

PHARMACOTHERAPY, 2001, 21 (12) :1468-1472

[7] Torsade de pointes: the clinical considerations [J].

Gowda, RM ;

Khan, IA ;

Wilbur, SL ;

Vasavada, BC ;

Sacchi, TJ .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2004, 96 (01) :1-6

[8] Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias [J].

Napolitano, C ;

Schwartz, PJ ;

Brown, AM ;

Ronchetti, E ;

Bianchi, L ;

Pinnavaia, A ;

Acquaro, G ;

Priori, SG .

JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2000, 11 (06) :691-696

[9] A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].

NARANJO, CA ;

BUSTO, U ;

SELLERS, EM ;

SANDOR, P ;

RUIZ, I ;

ROBERTS, EA ;

JANECEK, E ;

DOMECQ, C ;

GREENBLATT, DJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245

[10] Effects of three fluoroquinolones on QT interval in healthy adults after single doses [J].

Noel, GJ ;

Natarajan, J ;

Chien, SC ;

Hunt, TL ;

Goodman, DB ;

Abels, R .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (04) :292-303

← 1 2 →